Hybrid Micro-macro Electrodes in Patients With Epilepsy

Official title

Hybrid Micro-macro Electrodes to Record the Activity of Single Neurons During Seizures in Patients Who Suffer From Epilepsy

Overview

The aim of the MicroEPI study is to know whether it is possible to use safely a medical device (a micro-electrode) that allows recording the activity of neurons in the human brain. Patients who suffer from drug-resistant epilepsy and who are candidates to epilepsy surgery to alleviate their condition sometimes require the implantation of intracranial EEG electrodes for a few weeks, in order to determine as best as possible which region of the brain to operate on. In the MicroEPI study, some of these electrodes will also comprise micro-electrodes, allowing us to record the activity of the patients' neurons during their epileptic seizures.

Detailed description

Epilepsy is a common disease of the brain that can be severe or even cause death. What we call epilepsy is a tendency to suffer from epileptic seizures, which themselves consist in symptoms (e.g. loss of consciousness, involuntary movements, abnormal sensations like hallucinations) caused by abnormally intense or synchronized activity of the brain's neurons. However, we still understand very poorly what exactly goes on at the level of neurons in the human brain during an epileptic seizure. This knowledge gap is due to the fact that the brain's neurons are very small structures and are very well protected by the skull, and are therefore hard to study in human beings. Gaining a better understanding of how neuronal activity goes awry during epileptic seizures could lead to better ways to treat this disease.

In the MicroEPI study, a medical device called micro-macro electrode (MME), manufactured by the company Dixi Medical (France), will be implanted in the brain of patients who must anyway receive intracranial EEG electrodes. These MME electrodes will replace one or a handful of conventional intracranial EEG electrodes. The implantation surgery will be performed in the operating room, under general anesthesia, by an experienced neurosurgeon. The electrodes will remain implanted for 2 to 4 weeks, with the exact duration depending on the time required for the clinical team caring for the patient to collect enough information on the patient's epilepsy. During the entire duration of the electrodes' implantation, the patient will remain hospitalized, and the electrical signals from their brain will be recorded continuously. At the end of this period, the electrodes will be explanted in the operating room. The safety of the MME electrodes, expressed in terms of the number of adverse events attributable to the MME, will be compared to current data on the safety of conventional intracranial EEG electrodes. The performance of the MME electrodes, in terms of the number of recorded neurons, will also be measured.

Interventions

• Device micro-macro electrode implantation
  One or a handful of micro-macro electrodes are implanted for 2-4 weeks in patients undergoing epilepsy monitoring with intracranial EEG electrodes.

Primary outcome measures

• Adverse events (safety outcome) [Time frame: approximately 30 days]

Secondary outcome measures (2)

• Device malfunctions (performance outcome 1) [Time frame: approximately 30 days]
• Number of neurons recorded (performance outcome 2) [Time frame: approximately 30 days]

Eligibility criteria

Inclusion criteria

• Patient 18 years old or older suffering from drug-resistant focal epilepsy.
• Candidate for epilepsy surgery.
• Requires evaluation with intracranial stereo-EEG electrodes.
• Able and willing to provide informed consent.

Exclusion criteria

• Any acute infection (e.g. fever, throat infection).
• Skin or scalp infection over the implantation site.
• Thin or fragile skull bones, which would prevent stereo-EEG electrodes from being anchored safely.
• Increased risk of infections, either from a medical condition or from immunosuppressant medication.
• Increased risk of bleeding, either from a medical condition or from antiplatelet or anticoagulant medication.
• Severe concomitant medical disease (including, but not limited to, cardiovascular, respiratory, renal or hepatic disease).
• Severe concomitant psychiatric disease or major psychological distress.
• Women who are pregnant or breastfeeding during the study.
• Patients who have an implanted stimulation device (e.g. pacemaker, defibrillator, neurostimulator).

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation

N/A

Model

Single group

Masking

Open label

Primary purpose

Other

Study locations

Switzerland · 2 centers

• Inselspital Bern — Bern
• Hôpitaux Universitaires de Genève — Geneva

Identifiers

NCT: NCT05335187 · 2022-D0033 · 194507 · 10001031

Primary sources (government registries)

• ClinicalTrials.gov (US NIH)

View this study on ClinicalTrials.gov ↗